Group items tagged

Thornton & Ross is all set to expand its consumer healthcare offering by acquiring the well-established Opticrom eye-drops brand from Sanofi in the UK. Opticrom forms part of a wider transaction between Thornton & Ross' parent group, STADA, and Sanofi for eight local consumer healthcare brands across several countries, including Belgium, Germany, Hungary, Spain and the UK. The transaction will be financed with a combination of cash on balance sheet and existing facilities, and is scheduled to close in the fourth quarter of 2023, subject to customary approvals of relevant regulatory authorities. Opticrom Allergy 10ml bottle and 20 single doses for itchy, watery, red and inflamed eyes can be found behind the pharmacy counter, while Opticrom Hayfever 10ml bottle is available to purchase via self-selection to soothe and relieve eye symptoms of hayfever. These non-prescription medicines contain 20 mg/1ml sodium cromoglicate (2.0% w/v) and offer relief within 2 minutes.

The life cycle management company, Pharmanovia, has appointed Nivedita Valentine as associate vice president of Product Innovation. Ms Valentine will oversee the company's product innovation operations and decision-making as Pharmanovia continues to focus efforts on both, identifying new prospects to enhance lifecycle management of its brands through incremental innovation. She will report to interim chief scientific officer Stephen Deacon and help bridge unmet patient needs with the help of novel therapies, originating both from in-house development and through partnerships. Ms Valentine currently holds positions on the value-added medicines committee within Medicines for Europe and the International Rare Diseases Research Consortium (IRDiRC) Task Force on Drug Repurposing Guidebook. Pharmanovia CEO Dr James Burt commented: "Digitalisation and utilising the latest technological innovation are notable areas of acceleration within the pharma industry and Nivedita's appointment will ensure iconic brands will continue to be improved, supported, and used sustainably.

HRA pharma has announced the resignation of David Wright who moves on after serving the company for more than five years as chief executive officer. The company has appointed Martyn Hilton, chief commercial officer for HRA Pharma, as interim CEO effective from September 1, 2022. David helmed the company during a period of transformation and set the course for its tremendous growth, elevating HRA Pharma into a leading provider of over-the-counter self-care products. He commented: "Given the significant progress HRA has made, along with my personal goals after leading HRA for more than five years, I believe now is the time to step away from the business. "I am proud of all that we have accomplished, making HRA well-known for its Women's Health, Wound Care and Scar Care leadership, operating via brands including ellaOne, Hana, Compeed and Mederma. I appreciate all the team members involved in the success of the organization and believe Perrigo and HRA are well-positioned to elevate this business and these brands to the next level."

Bestway operates approximately 750 pharmacies nationwide in the UK under the Well brand. In April 2023, it completed its acquisition of Lexon, which operates 46 pharmacies in the UK under the Knights Pharmacy brand, and Asurex, a wholesale perfume supplier. On 26th May 2023, CMA announced the launch of its merger inquiry. A fast-track Phase 1 investigation found that the merger could lead to a significant lessening of competition between retail pharmacies in 12 local areas located in Liverpool and North East England. The merging businesses conceded that the deal raises competition concerns in these areas and have submitted proposals to sell pharmacies within these areas to restore the competition that would otherwise be lost as a result of the deal. Colin Raftery, CMA Senior Director of Mergers, said: "Pharmacies are essential public health services, and it's vital that the loss of competition brought about by a deal like this shouldn't leave people with reduced choice or worse services when they need medical support. The CMA will now carefully consider whether the remedy put forward by Bestway will address its concerns and ensure that customers in the affected areas continue to have access to good quality chemists.

The government, NHS England and the Association of the British Pharmaceutical Industry (ABPI) has begun the negotiations for a new voluntary scheme for branded medicines pricing on Thursday (4 May). A new voluntary scheme is expected to take effect from 1 January 2024, replacing the current scheme which came into force in 2019 and ends on 31 December 2023 In their first meeting, the government, NHS England and industry - represented by the ABPI -expected to agree to a shared negotiation aim of working toward a mutually beneficial agreement that supports better patient outcomes and a healthier population, a financially sustainable NHS, and UK economic growth. Health Minister, Will Quince, said: "These negotiations will ensure a new scheme continues to deliver value for money by providing significant savings for our health services, securing access to innovative lifesaving drugs for NHS patients, and helping to reduce waiting times - one of the Prime Minister's 5 priorities. The current voluntary scheme supports investment in NHS services and saves billions of pounds for the NHS, while also promoting innovations and a successful life sciences sector.

The Department of Health and Social Care (DHSC) has introduced new arrangements for the application of discount deduction to community pharmacy payments which will be implemented in six financial quarters beginning in October 2022 and concluding in January 2024. Under the new discount deduction system, the current single scale will be split into three groups: one each for generic medicines, branded medicines, and appliances. Separate fixed deduction rates have been determined for each group. This will provide all pharmacies the same rates of deduction applied to their reimbursement for the three different groups, regardless of the total value of that reimbursement. Fin McCaul, PSNC member and independent community pharmacy contractor, said: "The discount deduction scale has been a point of contention for contractors for many years, and PSNC has long been pushing to remedy this. "The incoming changes are designed to both improve equity of access to margin and manage the distortions presented by branded medicines, which just don't have the same level of discount available as generics.

The Department of Health and Social Care (DHSC) has published the full text of the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG). The 2024 VPAG agreement text sets out the detailed terms of the agreement reached between DHSC, NHS England and the Association of the British Pharmaceutical Industry (ABPI) to support patient access to medicines, the financial sustainability of the NHS and the UK life sciences sector. The new voluntary scheme will come into force on 1 January 2024, following expiry of the 2019 Voluntary Scheme and shall remain in force for a period of five years, until 31 December 2028. Manufacturers or suppliers of branded medicines to the NHS have been given time till 15 January 2024 to decide whether to join the new 2024 Voluntary Scheme, or default to the updated Statutory Scheme.

Drug shortages have become a global issue, with many countries struggling to maintain a consistent supply of common medications, including antidepressants, immunosuppressants and drugs to treat type 2 diabetes and ADHD. Earlier last month, the British Generic Manufacturers Association (BGMA), the trade body for off-patent medicines, warned that 111 products were facing supply problems, the highest on record in the UK, and more than double the number recorded at the start of 2022. More than half of products affected (55) are branded generic drugs, which represent 10 per cent of prescription products used in the UK. The trade body blamed the escalating rebate rate of the government's voluntary scheme for branded medicine pricing and access (VPAS) for these shortages, but Brexit is also cited as another reason for the problem.

Maxwellia has appointed Ian Adamson as strategic advisor to shape the next phase of pharmacy medicine launches - a process which involves identifying and converting suitable prescription only medicines into versions people can choose to buy under the supervision of a pharmacist. Ian brings over 30 years' international consumer health and personal care experience to the Maxwellia team. He is currently an advisor to the board of the UK independent pharmacy chain Day Lewis plc, an advisor to the board of Spanish healthcare company ReVa Europe S.L and board advisor to East Midlands Pharmaceuticals Ltd. Prior to this Ian was Chief Commercial Officer and a main board director at SSL International plc (prior to its sale to Reckitt Benckiser) with responsibility for a $1bn portfolio of brands, which included Durex and Scholl. Ian's appointment follows the landmark reclassification of the progestogen only pill by the MHRA, a change spearheaded by Maxwellia, and the company's subsequent launch of its first product Lovima in July 2021; and the current MHRA public consultation on the reclassification of Maxwellia's new pharmacy brand, Aquiette 2.5mg Tablets (Oxybutynin Hydrochloride) for the treatment of overactive bladder symptoms which are not adequately controlled by bladder training alone.

It's more than a brand name - Stomp Apparel has the quality and comfort to give you the confidence you need to get active, feel good about yourself and just look forward to the next hill.

It's more than a brand name - Stomp Apparel has the quality and comfort to give you the confidence you need to get active, feel good about yourself and just look forward to the next hill.

The government has launched a consultation into radically changing the Statutory Scheme for branded medicines (known as the Statutory Scheme). The consultation comes as delicate negotiations for replacing the alternative Voluntary Scheme are underway, potentially undermining these talks, while also further damaging industry confidence in the UK as a viable place to research, launch and supply medicine. The government proposals seek to hold average revenue clawback rates under the Statutory Scheme at historic highs of between 21-27%, compared to the pre-pandemic averages of 9.4% for the Statutory Scheme (2019-2021), and 6.88% for the Voluntary Scheme (2014-2021). The accompanying cost-benefit analysis ignores any negative impact this may have on medicine supply and wrongly claims it will boost investment. The consultation comes on the heels of government data last week showing UK life sciences foreign direct investment (FDI) fell by 47% between 2021 and 2022, down by £900m year on year. This large fall in investment coincided with a rise in the main UK clawback rate under the Voluntary Scheme from 5% to 15%, and led to the UK falling from 2nd to 9th out of 18 comparator countries for life sciences FDI in 2022. The Voluntary Scheme clawback rate now sits at a record 26.5% in 2023.

We are over the moon to break the news that your favourite health supplement brand in India got recognition as the "Top 10 Best Nutraceuticals Startups In India - 2022.

The Medicines and Healthcare products Regulatory Agency (MHRA) has cautioned people to stop using certain eye gels, highlighting a potential risk of microbial contamination that can cause an infection. As a precaution, the agency on Friday announced recall of specific batches of carbomer-containing lubricating eye gels branded Aacarb, Aacomer and Puroptics, which are generally used to relieve the symptoms of dry eye. Burkholderia cenocepacia is suspected to have caused the microbial contamination, and the issue was raised after an ongoing investigation conducted by UK Health Security Agency (UKHSA) identified a small number of cases of infection. Investigations are on to determine if there is a link between these products and the infections which have been identified. Meanwhile, retailers have been told to withdraw the affected products, and users are asked to return their product to the place of purchase immediately.

Bas Vorsteveld has been elected as the new president of PAGB, the trade association representing the manufacturers of branded OTC medicines, self care medical devices and food supplements. Vorsteveld, who is vice president and general Manager of Haleon GB and Ireland, succeeds Neil Lister, managing director UK & Ireland and vice president at Perrigo. PAGB said the appointment comes at a crucial time for the consumer healthcare association as it looks to expand the role of self-care, secure a long-term favourable business environment for members, adapt to environmental challenges and continue to deliver excellent services for members. "We are so pleased to welcome Bas to the role of President. Bas has been actively involved with PAGB as a board member and we're looking forward to continuing our work with him. I have already seen from Bas's time on our Board that he combines great sector knowledge with drive, energy and genuine passion for what we do and we're so excited to have him as our President," Michelle Riddalls, chief executive of PAGB, said. "Bas's input and guidance as our strategy evolves over the coming years will be vital as we respond to new challenges as they emerge and make the most of the opportunities ahead."

An abortion pill is composed of two kinds of generic called as Mifepristone and Misoprostol. These generics are marketed under different brand names Mifepristone is marketed in the name of RU-486, Korlym, Mifeprex, and Mifegyne another one that is Misoprostol is being sold in the name of Cytotec...

Be sure they specialize in eyeglass repair of your specific type of glasses. With the various brands & types of glasses, be sure yours are in gook, capable hands. You can trust the professionals at Overland Optical. We are a leading medical eye care provider, offering a high level of experience & expertise to families in the St. Louis, Missouri.

Family Eye Care has hundreds of eyewear glasses styles in the Missouri area. We are providing different brand of eyewear glasses in St. Louis, Overland, Maryland Heights, Bridgeton, St. Charles, St. Peters, Wentzville and O'Fallon area.

Origin of life has always been a mystery to the man-kind, which further raised a query on how a single-cell turned out to be multi-celled organism.

Origin of life has always been a mystery to the man-kind, which further raised a query on how a single-cell turned out to be multi-celled organism.

MTP Kit is the brand that encloses two USFDA approved generic modules Mifepristone and Misoprostol. The Mifepristone functions to inhibit the surge of Progesterone hormone, the one that is crucial for the development of the fetus as it supplies the oxygen and nutrition to the fetal tissues...

&Me, a Bangalore headquartered startup, is the proud seller of India's first menstrual drink. The brand is founded by Ankur Goyal, an alumnus of Stanford business school. Matrix partners and Sauce.vc. together are set to invest $ 1 million (INR 7 crores approx.) in &Me. RoC filings show that they have invested in new shares of &Me's parent company called Merhaki Foods and Nutrition.